文献速递高血压

Tonlamarsen治疗未控制高血压的疗效:KARDINAL 2期随机临床试验

Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial.
PubMed 文献 · J Am Coll Cardiol · 2026-03-28

KARDINAL 2期试验纳入正在服用2至5种降压药且诊室收缩压>135 mm Hg的成人,先接受4周安慰剂导入,再接受单剂tonlamarsen 90 mg主动导入后随机分组,分别接受每月一次共4次tonlamarsen或安慰剂至16周。主要终点为第20周血浆血管紧张素原和诊室收缩压较基线的组间差异。结果显示每月tonlamarsen较单剂加安慰剂更显著降低血管紧张素原,但血压降幅无额外获益。

要点

  • 每月tonlamarsen较单剂加安慰剂显著降低血浆血管紧张素原,差异为-44.1%。
  • 诊室收缩压降幅两组均为-6.7 mm Hg,组间差异-0.1 mm Hg无统计学意义。
  • 严重不良事件少见且两组相似。

核心结论

  • 在未控制高血压患者中,每月tonlamarsen较单剂tonlamarsen后安慰剂更有效降低血浆血管紧张素原,但未带来额外血压下降。

研究设计与样本

  • 随机、安慰剂对照2期试验,纳入诊室收缩压>135 mm Hg且服用2至5种降压药的成人。
  • 279例接受安慰剂导入,206例接受单剂tonlamarsen 90 mg主动导入,198例随机分组。
  • 随机后接受每月一次共4次tonlamarsen 90 mg皮下注射或匹配安慰剂,为期16周。
  • 共同主要终点为第20周血浆血管紧张素原和诊室收缩压较基线的组间差异。

主要发现

  • 第20周血浆血管紧张素原最小二乘均值百分比变化:单剂后安慰剂组-23.0%(95% CI: -27.8%至-18.2%),每月tonlamarsen组-67.2%(95% CI: -71.9%至-62.4%)。
  • 血管紧张素原组间最小二乘均值差异为-44.1%(97.5% CI: -51.9%至-36.4%;P < 0.0001)。
  • 诊室收缩压最小二乘均值变化:单剂后安慰剂组-6.7 mm Hg(95% CI: -9.8至-3.5 mm Hg),每月tonlamarsen组-6.7 mm Hg(95% CI: -9.8至-3.6 mm Hg)。
  • 收缩压组间最小二乘均值差异为-0.1 mm Hg(95% CI: -4.5至4.4 mm Hg;P = 0.97)。
  • 严重不良事件少见且两组相似。

关键数值与推荐

  • 入组标准:诊室收缩压>135 mm Hg且正在服用2至5种降压药物。
  • 干预方案:tonlamarsen 90 mg皮下注射,每月一次,共5个月(主动导入1剂+随机后4剂)。
  • 共同主要终点:第20周血浆血管紧张素原和诊室收缩压较基线的组间差异。

临床怎么用

  • 每月tonlamarsen可显著降低血浆血管紧张素原,但在本试验中未转化为额外诊室收缩压下降。
  • 在未控制高血压患者中,tonlamarsen的降压疗效尚需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angiotensinogen production represents the rate-limiting step in activation of the renin-angiotensin-aldosterone system. Tonlamarsen is an investigational antisense oligonucleotide directed against hepatic angiotensinogen synthesis; its efficacy and safety among patients with hypertension are unknown. OBJECTIVES: The aim of this study was to assess the safety and efficacy of 90 mg tonlamarsen administered subcutaneously once monthly for 5 months compared with a single dose of tonlamarsen and subsequent placebo. METHODS: This randomized, placebo-controlled trial enrolled adults with office systolic blood pressure (BP) >135 mm Hg receiving 2 to 5 antihypertensive medications. Participants entered a 3-part treatment period with monthly administration of the study drug, consisting of a 4-week placebo lead-in, followed by 4-week active run-in with a single dose of tonlamarsen and subsequent randomization to 4 additional doses of tonlamarsen or matching placebo for 16 weeks. The coprimary endpoints were the between-group differences in the change from baseline to week 20 in plasma angiotensinogen and in office systolic BP. RESULTS: A total of 279 participants received placebo lead-in, 206 received 90 mg tonlamarsen during the active run-in, and 198 were randomized. The mean BP among randomized participants before and after the placebo lead-in was 147/90 and 147/89 mm Hg, respectively. Following active run-in with tonlamarsen, the mean BP was 140/87 mm Hg. Twenty weeks following the first dose of tonlamarsen, least squares (LS) mean percentage changes in plasma angiotensinogen levels were -23.0% (95% CI: -27.8% to -18.2%) with a single dose of tonlamarsen and subsequent placebo and -67.2% (95% CI: -71.9% to -62.4%) with monthly tonlamarsen administration, with a LS mean difference of -44.1% (97.5% CI: -51.9% to -36.4%; P < 0.0001). The LS mean changes in office systolic BP were -6.7 mm Hg (95% CI: -9.8 to -3.5 mm Hg) for participants following a single dose of tonlamarsen and subsequent placebo and -6.7 mm Hg (95% CI: -9.8 to -3.6 mm Hg) for participants treated with monthly tonlamarsen, with a LS mean difference of -0.1 mm Hg (95% CI: -4.5 to -4.4 mm Hg; P = 0.97). Serious adverse events were infrequent and similar between treatment groups. CONCLUSIONS: Among individuals with uncontrolled hypertension, monthly tonlamarsen administration was more effective at lowering plasma angiotensinogen compared with a single tonlamarsen dose, but there was no additional BP reduction. (A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension [KARDINAL]; NCT06864104).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Laffin LJ, Wang Q, Sarraju A, et al. Efficacy of Tonlamarsen in Patients With Uncontrolled Hypertension: The KARDINAL Phase 2 Randomized Clinical Trial. J Am Coll Cardiol. 2026. PMID: 41949512. doi:10.1016/j.jacc.2026.03.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。